HANGZHOU, China and SAN FRANCISCO, July 11, 2021 / PRNewswire / – Hangzhou Sciwind Biosciences Co., Ltd., a rapidly growing clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for the treatment of chronic, metabolic, and immunological diseases, today announced the appointment of Dr. Weidong Zhong, former co-founder and managing director of Terns Pharmaceuticals, as Chief Strategy Officer and President of the US subsidiary Sciwind Biosciences United States.
“Dr. Zhong is a highly qualified industry leader with an extensive track record in discovering and developing innovative therapies for the treatment of infectious and metabolic diseases,” said Hello Pan, Ph.D., Founder and CEO of Sciwind. “His knowledge and expertise will be very valuable to Sciwind as we develop our differentiated product pipeline into China as well as in other global markets. We are very pleased that Dr. Zhong joins us at this critical point in our company’s growth history and leads our development activities for global markets. “
“I am very excited to come to Sciwind and to be part of this dedicated team focused on developing future generations of innovative therapies for patients with debilitating diseases China and worldwide. I look forward to using my knowledge and cross-border development experience to advance Sciwind’s exciting drug candidates, “commented Dr. Zhong.
Previously, Dr. Zhong Co-Founder and CEO and Chief Scientific Officer of Terns Pharmaceuticals, where he founded and led the company to build a world-class product pipeline for NASH and become a publicly traded biotech company in less than 4 years since its inception. Before founding Terns, Dr. Zhong Global Head of Antiviral Research at Novartis, where he oversaw antiviral drug discovery activities and was instrumental in building a strong drug candidate pipeline. Before joining Novartis, Dr. Zhong Senior Director of Biology at Gilead Sciences where he led the discovery efforts against HCV, HBV and liver fibrosis. At Gilead, Dr. Zhong played a critical role in building a strong portfolio of direct-acting HCV antiviral drugs and was instrumental in meeting these global public health needs. At the beginning of his career, Dr. Zhong held senior research positions with increasing responsibility at Valeant Pharmaceuticals, Schering-Plow Research Institute and SmithKline Beecham.
Sciwind Biosciences is a cross-border biopharmaceutical company focused on the discovery and development of innovative therapies for the treatment of chronic, metabolic and immunological diseases. The product pipeline consists of potentially world-class biological drug candidates. Sciwind has also developed several proprietary technologies, including platforms for the delivery of oral peptides and inhaled protein therapeutics, and has identified a number of drug candidates based on these core platform technologies. For more information please contact us vhe [email protected].
SOURCE Hangzhou Sciwind Biosciences Co., Ltd.